Tech Review

Dealmaking in 2012 off to a good start

05.03.2012



European dealmaking numbers went up in 2011, but what will 2012 look like? It’s still early days, but the year has already seen some major agreements and take­overs. With the exception of Roche, which has issued a US$5.7bn hostile bid for Illumina Inc., most of the activity is dominated by US companies like Amgen, Bristol-Myers-Squibb and Celgene. Because many antibody patents run out this year, however, the bio­similars sector in particular is expected to see a lot more action.

By 2017, biologics revenues of US$60bn are in danger due to patent expiry, according to an analysis by Burrill & Co. Despite its special requirements, biosimilar development has become a very popular area.
None of the currently approved biosimilars comes even close to antibodies in terms of complexity, but financial incentives make the idea of biosimilar antibodies tempting. Remicade (US$4bn in annual sales) goes off-patent in Europe in 2014. Herceptin (US$5.7bn) and Rituxan (US$5.5bn) follow in the same year and 2015, respectively.
One of the most active players in the market is Merck & Co. The US pharma is aiming to have five biosimilars in late-stage testing by 2011. To do so, it has formed various alliances. Merck’s new friends include the CRO Parexel and South Korean manufacturer Hanwha Chemical. The partners are currently trying to bring to market a generic version of the fusion protein Enbrel (sales of US$6.2bn in 2010). And there are new players in the sector, including Samsung. The South Korean electronics conglomerate known for mobile phones and flat-screen TVs has identified biologics as a promising target. Over the next 10 years, it’s investing US$1.9bn in the area. Even Amgen, not long ago one of the strongest opponents of biosimilars, has teamed up with Watson Pharmaceuticals to develop and commercialise biosimilar oncology drugs, among them many antibodies.

Politics / Law

23.03.2012

Brussels/Strasbourg – Health claims are set to be drastically limited in the EU. On Wednesday 21 March the Environment Committee of the European Parliament confirmed a proposal of the European Commission to prohibit 1,600 health...

Politics / Law

15.03.2012

Parma/Stockholm – Foodborne bacteria such as Salmonella and Campylobacter are becoming more and more resistant to antimicrobial drugs, according to a joint report published by the European food watchdog EFSA and the European...

BioFunding

09.03.2012

In mid-February, scientists and entrepreneurs from nine EU countries met at the Center for Genomic Regulation (CRG) in Barcelona to launch the 4DCellFate project. Positioned within the FP7 Programme, the consortium will receive...

BioFunding

09.03.2012

Brussels – The EU’s Innovative Medicines Initiative (IMI) will establish the European Lead Factory, an EU-wide public-private partnership aiming to facilitate drug discovery efforts. The Lead Factory will comprise a...

Editorial

07.03.2012

T    he societal and economic challenges facing Europe and the world are complex and interconnected. The Bioeconomy Strategy and Action Plan “Innovating for Sustainable Growth: a Bioeconomy for Europe”, which was adopted by the...

Tech Review

07.03.2012

Intellectual Property (IP) is without question one of the most vital aspects of any bio­tech venture, a key and undisputed factor for success. However, most bio­tech companies are still incapable of unlocking the value of their...

Clinical Trial

07.03.2012

Schlieren – Swiss Cytos Biotechnology Ltd. has been authorised to restructure a convertible bond by Canton of Zurich authorities. The company does not have enough cash to pay it back. Negotiations with bond holders failed in a...

Clinical Trial

06.03.2012

Munich – German 4SC AG jumped 39% to €2.05/share after oncology drug candidate resminostat met the primary endpoint of at least a 20% progression-free survival rate in a Phase II trial to treat patients with hepatocellular...

Editorial

06.03.2012

The start of 2012 witnessed the tides turning in favour of small and mid-cap names in the European Life Sciences sector. Major global biotechnology indices like the NBI, BTK, and BIOTK are up over 15% year to date. The pace of...

Displaying results 1 to 10 out of 1982

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive/article/dealmaking-in-2012-off-to-a-good-start.html

Product of the week

Products

Events

All Events

Current issue

All issues